News

Video

Gene Variant May Predict Side Effects From Kidney Cancer Immunotherapy

Fact checked by:

A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.

A gene linked to immune system function may help predict which patients with kidney cancer are more likely to experience side effects from immunotherapy, according to research highlighted by Dr. Emre Yekedüz.

The findings, which will be presented by Dr. Eddy Saad at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight a specific variation in the interleukin-7 (IL-7) gene. This single nucleotide polymorphism was associated with a higher risk of immune-related adverse events, or side effects, in patients receiving treatment.

Side effects of grade 2 (moderate) or higher occurred in 33.3% of patients treated with Opdivo (nivolumab) and 40.4% of those treated with Afinitor (everolimus). In the Opdivo arm, the most common side effects were skin-related (21%), liver-related (16.8%) and endocrine (15.8%). In the Afinitor arm, respiratory (30.1%), skin-related (22.3%) and gastrointestinal (19.4%) side effects were most common.

The rate of grade 2 or higher side effects was significantly higher in variant-positive patients compared with variant-negative patients treated with Opdivo, this pattern was not observed in patients receiving Afinitor. Recurrent side effects followed a similar pattern, with higher rates in variant-positive patients receiving Opdivo and a possible trend toward lower rates in those receiving Afinitor.

This finding could lead to more personalized strategies for reducing toxicity in patients with kidney cancer, as per Yekedüz.

Yekedüz is a medical oncologist and research fellow in medicine at Dana-Farber Cancer Institute in Boston.

Transcript:

Are there any noteworthy studies being presented at the 2025 ASCO Annual Meeting that could help patients better understand or manage potential side effects from immunotherapy?

I’d like to highlight a poster [being presented at the 2025 ASCO Annual Meeting] that will be presented during the poster session. It evaluates the role of the interleukin-7 (IL-7) gene, which is involved in immune pathways for patients receiving immunotherapy. The study, to be presented by Dr. Eddy Saad from Dana-Farber Cancer Institute, found that a single nucleotide polymorphism in IL-7 is associated with an increased risk of immune-related side effects in these patients.

Moving forward, we may be able to use this information to identify patients at higher risk for these side effects and reduce toxicity for those with renal cell carcinoma.

Transcript has been edited for clarity and conciseness

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.